Rocket Pharmaceuticals, Inc. Common Stock RCKT
$3.47
+3.89%
at last close
Market Cap$380.92 million
P/E Ratio—
Div Yield—
Volume1.16M
52-Week Range
$2.53$5.45
Analyst Ratings
- Consensus
- Hold — 4 Buy · 1 Hold · 2 Sell (7 analysts)
- Avg. Price Target
- $45.43 (+1209.2% upside)
Key Stats
- Today's Range
- $3.27 – $3.50
- 50-Day Range
- $2.53 – $4.33
- 52-Week Range
- $2.53 – $5.45
- Volume
- 1.16 million shs
- Average Volume
- 1.72 million shs
- Market Cap
- $380.92 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.38%
- Days to Cover
- 2.34
About Rocket Pharmaceuticals, Inc. Common Stock
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Related Stocks
Compare head-to-head: RCKT vs LLY·RCKT vs JNJ·RCKT vs ABBV·RCKT vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.